Gene therapy vector for modulation of hair growth via C. acnes
Eligo Bioscience presents a novel gene therapy vector to modulate hair growth by delivering genetic circuits into Cutibacterium acnes. This innovative approach enables local expression of biologics in hair follicles to impact hair growth cycle regulation.
Overview
Eligo Bioscience has developed an innovative gene therapy vector designed to modulate the hair growth cycle through the skin's microbiome. By targeting Cutibacterium acnes, the most abundant skin commensal, this technology delivers genetic circuits directly into the bacteria in vivo. This approach allows for the local expression of novel genes in hair follicles, enabling precise modulation of hair growth via biologics.
Technical specifications
- Unique delivery vector capable of in vivo genetic circuit incorporation into C. acnes.
- Genetic circuits are designed to express specific biologics that target pathways involved in hair growth regulation.
- Current development involves multiple versions of genetic circuits, each tailored to a specific biologic's action on the hair growth cycle.
- Validation includes animal and ex vivo models to assess hair growth impact, with plans for human trials using the most promising candidates.
Technology readiness level
The gene therapy vector is currently at Technology Readiness Level 3, having been tested in controlled environments and preparing for further validation through animal and ex vivo models.
About Eligo Bioscience
Eligo Bioscience (founded 2014) is a microbiome biotech company building “eligobiotics” – CRISPR-carrying phages to precisely edit or eliminate bacteria. Initially focusing on medical applications (like treating gut infections), it exemplifies the broader potential of CRISPR phage technology.
delivered to your inbox.